Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase I study of gemcitabine plus lapatinib in women with advanced breast cancer
NL-OMON30513Phase 1Not yet recruiting
- Sponsor
- Netherlands Cancer Institute
- Start
- Apr 2007
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label trial of gemcitabine and lapatinib in breast cancer, sponsored by Netherlands Cancer Institute. Planned start Apr 2007; status: not yet recruiting.
02
Drugs
gemcitabinelapatinib
03
Conditions
breast cancer
Beyond the preview
Go deeper on NL-OMON30513.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON30513.